The European Patent Office ("EPO") currently requires applicants to adapt descriptions to allowable claims. This practice is risky, expensive, and not clearly grounded in the law....more
In December, we reported that the European Commission ("Commission") had issued an Interpretive Notice (2016/C 411/03) stating products produced by essentially biological processes should not be patentable. The notice came as...more
7/17/2017
/ Biologics ,
Biotechnology ,
EU ,
European Commission ,
European Patent Convention ,
European Patent Office ,
Genetically Engineered Animals ,
Patent Applications ,
Patent-Eligible Subject Matter ,
Patents ,
Plant Patents ,
Product Exclusivity ,
Subject Matter Conflicts ,
The Enlarged Board of Appeals